Navigation Links
Merge Technologies Receives Expected Additional NASDAQ Notification
Date:11/16/2007

Company expects to satisfy all requirements for continued listing and make

all necessary filings by December 31, 2007

MILWAUKEE, Nov. 16 /PRNewswire-FirstCall/ -- Merge Technologies Incorporated, d.b.a. Merge Healthcare (Nasdaq: MRGE; TSX: MRG) (the "Company") today announced that the Company received a written notification from the staff of The NASDAQ Stock Market on November 13, 2007, stating that the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 would serve as an additional basis for delisting the Company's common stock from The NASDAQ Stock Market. The Company expected to receive the NASDAQ notification due to the Company not filing its Form 10-Q for the quarter ended September 30, 2007. This notification is in addition to prior NASDAQ staff notifications stating that the common stock was subject to delisting because the Company did not timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/MRGELOGO)

The Company previously announced its receipt of a written notification from the NASDAQ Listing Qualifications Panel stating that the panel determined to continue the listing of the Company's common stock on the NASDAQ Global Market, subject to the Company's filing its Form 10-Q for the quarter ended June 30, 2007 and all required restatements by no later than January 29, 2008. The Company will also need to file its Form 10-Q for the quarter ended September 30, 2007 by that date to regain compliance with the NASDAQ listing standards. The Company expects that it wil
'/>"/>

SOURCE Merge Technologies Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
2. Climatic variations influence the emergence of cholera in Africa
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
5. Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger
6. ISS and Glass Lewis Recommend Cholestech Stockholders Vote FOR Merger
7. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
8. Exceptional Childrens Foundation Merger with Kayne Eras Center Creates One of States Most Comprehensive Nonprofits Serving the Disabled
9. GSI Securitization Completes Merger and Domicile Transfer
10. Hologic Sets Special Meeting of Stockholders to Vote on Proposed Merger with Cytyc Corporation
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...rned patients on anti-depressants against taking w...lth's Medicines and Healthcare products Regulatory... of psychiatric reactions to drug, marketed as Aco...364) psychiatric reactions have been reported," it...
...crore Indian health insurance industry is poised t...wth rate of over 44 per cent per annum, it is one ...urers and even life insurers are jumping in the fr... Corporation of India (LIC), for instance, is pla...
..., for her upcoming tour bosses have asked her to s...he gig is over . According to a source, although ...by soon, she was bugged by the contract as no othe... to sign such contract. Its just a practical requ...
...rks about her, claiming that the actress is too ol...utcher tied the knot in September 2005, and the ac...by. Lesley Guynes, who is separated from Moores h...hat the 44-year-old actress was unable to have kid...
Other Medicine News:Health News:UK Reports Psychiatric Reactions to Weight-loss Drug Rimonabant 2Health News:Life Insurers in India to Launch Health Insurance Policies 2
(Date:9/4/2008)...stralia, Sept. 4 /- Cytopia Limited (...rolment for its Phase Ib/II,study of CYT997, the c...t,in patients with an aggressive form of brain ca... GBM clinical trial is the first Phase II efficacy... for the company and the second in its,suite of Ph...
(Date:9/4/2008)...ished in ,The Lancet, and Presented at ESC Congres... from a new international,study, the GISSI Heart F...,omega-3 acid ethyl esters reduced all cause morta...asons in patients with chronic heart,failure. Thes...sion of ,The,Lancet, and were presented at the Eur...
(Date:9/4/2008)...erland, September 4 /- Axentis Pharma...sess the safety and tolerability,of a new therapeu...ary,infection in cystic fibrosis patients. The new...nt to be delivered directly to the site of,infecti...fects of two,different doses of the new drug. Init...
(Date:9/4/2008)...ents Remain on Schedule with Two Abstracts Accepte...lease in November 2008, BRIDGEWATER, N.J., Sept. ...a specialty pharmaceutical company focused on the ... today announced the appointment of,Peter L. Garra...Peter Garrambone,s career includes more than 50 ph...
Breaking Medicine Technology:Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 1URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 2URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 3URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 4URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 5Keryx Biopharmaceuticals to Present at the Jefferies 26 Co Healthcare Conference 6180 1Keryx Biopharmaceuticals to Present at the Jefferies 26 Co Healthcare Conference 6180 2New Generation Biofuels Set to Join Russell Microcap Index 6178 1New Generation Biofuels Set to Join Russell Microcap Index 6178 2New Generation Biofuels Set to Join Russell Microcap Index 6178 3Astellas Launches Lexiscan 28TM 29 28Regadenoson 29 Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging 2 6176 1Astellas Launches Lexiscan 28TM 29 28Regadenoson 29 Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging 2 6176 2Astellas Launches Lexiscan 28TM 29 28Regadenoson 29 Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging 2 6176 3
...reated with VELCADE, cyclophosphamide,and prednis...7 /PRNewswire-FirstCall/ -- Millennium,Pharmaceuti...esults,from clinical trials of VELCADE based thera...e response(1) (CR) rates in previously,treated mul...resented at the prestigious 11th International Mye...
... Greece, June 29, 2007 /PRNewswire/ --,The Europea...viously treated patients on REVLIMID (lenalidomide...ival of 35 months, nearly,three years. The data ar...e III trials that enrolled more than 700 patients,...dated results,were presented at the 11th Internati...
Other Medicine Technology:Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 2Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 3Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 4Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 5Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 6The European Myeloma Platform Reports New Survival data for,Revlimid Presented at the International Myeloma Workshop in Greece 2
...demand environments like OB/GYN, ER/Trauma, ICC/CC... delivers precision and control, plus consistent h...FESKIN* SATIN PLUS* Sterile Singles delive...excellent tactile sensitivity. The gloves are powd...
UROLOGY DRAPE. Soft translucent material for excellent shape conformity. Latex finger cot with additional adhesive ring around base. Full-width 50mm adhesive strip for secure fixing, with finger lift
NEAR-SkinTM Incise Drape Aggressive adhesive with no residue High moisture permeability for extended adhesion Low-glare matte finish film Product number identification
...the Penilab IV and the Penilab V have an exception...al studies. Model 1060 is similar to the Model 10...can one be added later. The Penilab V has a Doppl...of the accessories you'll need to get started. La...
Medicine Products: